公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2012 | BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) | Mok, T. S. K.; Lee, J. S.; Zhang, L.; Yu, C.; Thongprasert, S.; Ladrera, G. E. I.; Srimuninnimit, V.; Truman, M. I.; Klughammer, B.; Wu, Y. | Ann. Oncol. | | | |
2015 | Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC | Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M. | Ann. Oncol. | | | |
2012 | PIONEER: A PROSPECTIVE MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS (PATIENTS) WITH ADVANCED LUNG ADENOCARCINOMA (ADC) | Au, J. S. -K.; Yuankai, S.; Thongprasert, S.; Srinivasan, S.; Tsai, C. -M.; Khoa, M. T.; Heeroma, K.; Itoh, Y.; Cornelio, G.; Yang, P. -C. | Ann. Oncol. | | | |